Quest Diagnostics intends to offer $750,000,000 senior notes in public offering

Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $750,000,000 in aggregate principal amount in two series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The notes will be fully and unconditionally guaranteed on a senior, unsecured basis by certain of the Company's domestic, wholly owned subsidiaries.

The issuance of the notes will be subject to customary closing conditions. The Company intends to use the net proceeds from the offering to repurchase any notes tendered under its concurrent tender offer, and for general corporate purposes, including acquisitions, capital expenditures, share repurchases and repayment of other indebtedness. BofA Merrill Lynch, Morgan Stanley, RBS and Wells Fargo Securities will be joint book-running managers for the debt offering. When available, copies of the preliminary prospectus supplement and the accompanying base prospectus for the offering can be obtained from BofA Merrill Lynch toll-free at (800) 294-1322, Morgan Stanley toll-free at (866) 718-1649, RBS toll-free at (866) 884-2071 or Wells Fargo Securities toll-free at (800) 326-5897.

SOURCE Quest Diagnostics Incorporated